Safety of high-dose intravenous mistletoe therapy in pediatric cancer patients: A case series.
CONCLUSION: Our study underpinned the safety and feasibility of high-dose mistletoe infusion in children with advanced stages of cancer and showed noteworthy antineoplastic effects, which should be verified in a prospective clinical phase II/III-study. Because of possible side effects, the treatment should be implemented only in an in-patient setting in experienced pediatric oncology centers.
PMID: 30219449 [PubMed - in process]
Source: Complementary Therapies in Medicine - Category: Complementary Medicine Authors: Zuzak TJ, Wasmuth A, Bernitzki S, Schwermer M, Längler A Tags: Complement Ther Med Source Type: research
More News: Alternative and Complementary Therapies | Astrocytoma | Bone Cancers | Brain | Cancer | Cancer & Oncology | Children | Leukemia | Lymphoma | Mistletoe | Neuroblastoma | Neurology | Osteosarcoma | Pediatrics | Sarcomas | Soft Tissue Sarcoma | Study